(MedPage Today) — NEW ORLEANS — Despite ongoing scrutiny about its safety, nexiguran ziclumeran (nex-z) still had promising effectiveness data to hold onto.
In an update on nex-z’s phase I study, the CRISPR-Cas9 gene therapy stayed the course…
Source link : https://www.medpagetoday.com/meetingcoverage/aha/118460
Author :
Publish date : 2025-11-12 15:00:00
Copyright for syndicated content belongs to the linked Source.
